Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: August 30, 2022 Report Code: GDGMDHC22277IDB-ST

Select Item

Osteoporosis Pipeline Drugs Market Overview

Osteoporosis signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

The Osteoporosis pipeline drugs market research report provides an analysis of the Osteoporosis drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.

Key Targets Tumor Necrosis Factor Ligand Superfamily Member 11, Parathyroid Hormone Receptor, Sclerostin, Estrogen Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase, Peroxisome Proliferator Activated Receptor Gamma, Vitamin D Receptor, and Estrogen Receptor Beta
Key Mechanisms of Action Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor, Parathyroid Hormone Receptor Agonist, Sclerostin Inhibitor, Estrogen Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Vitamin D Receptor Agonist, and Estrogen Receptor Antagonist
Key Routes of Administration Subcutaneous, Oral, Parenteral, Intravenous, Transdermal, Inhalational, Intramuscular, Intravitreal, and Topical
Key Molecule Types Small Molecule, Monoclonal Antibody, Recombinant Peptide, Recombinant Protein, Synthetic Peptide, Peptide, Biologic, and Cell Therapy
Key Companies Omeros Corp, Affilogic SAS, Galapagos NV, Luye Pharma Group Ltd, Max Biopharma Inc, Uni-Bio Science Group Ltd, Amgen Inc, Angitia Biopharmaceuticals, Biocon Ltd, Celltrion Inc, and CSPC Pharmaceutical Group Ltd

Key Targets of the Osteoporosis Pipeline Drugs Market

Some of the targets of the Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11, Parathyroid Hormone Receptor, Sclerostin, Estrogen Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase, Peroxisome Proliferator Activated Receptor Gamma, Vitamin D Receptor, and Estrogen Receptor Beta among others.

Osteoporosis Pipeline Drugs Market, by Key Targets

Osteoporosis Pipeline Drugs Market, by Key Targets

For more insights on key targets, download a free report sample

Key Mechanisms of Action in the Osteoporosis Pipeline Drugs Market

The key mechanisms of action of the Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor, Parathyroid Hormone Receptor Agonist, Sclerostin Inhibitor, Estrogen Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Vitamin D Receptor Agonist, and Estrogen Receptor Antagonist among others.

Osteoporosis Pipeline Drugs Market, by Key Mechanisms of Action

Osteoporosis Pipeline Drugs Market, by Key Mechanisms of Action

For more insights on key mechanisms of action, download a free report sample

Key Routes of Administration in the Osteoporosis Pipeline Drugs Market

The routes of administration in the Osteoporosis pipeline drugs market are subcutaneous, oral, parenteral, intravenous, transdermal, inhalational, intramuscular, intravitreal, and topical among others.

Osteoporosis Pipeline Drugs Market, by Routes of Administration

Osteoporosis Pipeline Drugs Market, by Routes of Administration

For more insights on routes of administration, download a free report sample

Key Molecule Types in the Osteoporosis Pipeline Drugs Market

The molecule types in the Osteoporosis pipeline drugs market are Small Molecule, Monoclonal Antibody, Recombinant Peptide, Recombinant Protein, Synthetic Peptide, Peptide, Biologic, and Cell Therapy among others.

Osteoporosis Pipeline Drugs Market, by Molecule Types

Osteoporosis Pipeline Drugs Market, by Molecule Types

For more insights on molecule type, download a free report sample

Key Companies in the Osteoporosis Pipeline Drugs Market

Some of the key companies in the Osteoporosis drugs development pipeline drugs market are Omeros Corp, Affilogic SAS, Galapagos NV, Luye Pharma Group Ltd, Max Biopharma Inc, Uni-Bio Science Group Ltd, Amgen Inc, Angitia Biopharmaceuticals, Biocon Ltd, Celltrion Inc, and CSPC Pharmaceutical Group Ltd among others.

Amgen Inc: Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures, and markets innovative human therapeutics to treat patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience, and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television, and online media. Amgen is headquartered in Thousand Oaks, California, the US.

Osteoporosis Pipeline Drugs Market, by Companies

Osteoporosis Pipeline Drugs Market, by Companies

For more insights on companies, download a free report sample

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).

  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Abiogen Pharma SpA
Ablynx NV
Abreos Biosciences Inc
Aclaris Therapeutics Inc
Addpharma Inc
Aerami Therapeutics Inc
Affilogic SAS
AgeX Therapeutics Inc
Airsea (Taizhou) Pharmaceutical Ltd
AlphaMab Co Ltd
Alvotech SA
Amgen Inc
Amogen Pharma Pvt Ltd
Angitia Biopharmaceuticals
Aryogen Pharmed Co
Aveta Biomics Inc
Bainan Biotech ApS
Beijing Kangleweishi Biotechnology Co Ltd
Beijing Northland Biotech Co Ltd
Beryl Therapeutics Inc
Better Life Pharmaceuticals Inc
Biocon Ltd
Bone Biologics Corp
Cellatoz Therapeutics Inc
Celltrion Inc
China NT Pharma Group Co Ltd
ChoDang Pharm Co Ltd
Citragen Pharmaceuticals Inc
CK Regeon Inc
Clayton Biotechnologies Inc
Clonz Biotech Pvt Ltd
Corium Inc
CSPC Pharmaceutical Group Ltd
Curexsys GmbH
Daewoong Pharmaceutical Co Ltd
Dongkook Pharmaceutical Co Ltd
Eden Biologics Inc
Eli Lilly and Co
Endoceutics Inc
Enesi Pharma Ltd
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Epygen Biotech Pvt Ltd
Evgen Pharma Plc
Fresenius Kabi SwissBioSim GmbH
Galapagos NV
Gbiologics Inc
Gedeon Richter Plc
Genor BioPharma Co Ltd
Genu Pharma Co Ltd
GlycoNex Inc
GPN Therapeutics Inc
Haoma Medica Ltd
Helixmith Co Ltd
Histide AG
HNB Therapeutics LLC
Hualan Biological Engineering Inc
Huons Global Co Ltd
IMGENEX India Pvt Ltd
Immunwork Inc
InnoPharmaScreen Inc
Intas Pharmaceuticals Ltd
Ipsen SA
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Keros Therapeutics Inc
Kyoto Pharmaceutical Industries Ltd
Lactocore Inc
LBL Biotech Corp
Lead Discovery Center GmbH
LEXEO Therapeutics LLC
Link Biologics Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabxience Holding SL
Max Biopharma Inc
Merck & Co Inc
Mesentech Inc
Mezomax Inc
Nano Intelligent Biomedical Engineering Corp
Nanomedic Inc
NeuClone Pty Ltd
NovMetaPharma Co Ltd
Omeros Corp
Oncosimis Biotech Pvt Ltd
Ortho Regenics Pvt Ltd
OssiFi Inc
Paras Biopharmaceuticals Finland Oy
PhytoHealth Corp
Prestige BioPharma Ltd
PRG S&Tech Inc
Qilu Pharmaceutical Co Ltd
Radius Health Inc
Rani Therapeutics LLC
Regenerative Arthritis & Bone Medicine Inc
Reliance Life Sciences Pvt Ltd
Reven Holdings Inc
Ribomic Inc
Samsung Bioepis Co Ltd
Sandoz International GmbH
Shaanxi Micot Technology Co Ltd
Shandong New Time Pharmaceutical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Bioscience Co Ltd
Shanghai Mab Venture Biopharm Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shin Poong Pharm Co Ltd
Stelis Biopharma Ltd
Surrozen Inc
Suzhou Stainwei Biotech Inc
Taithera Inc
Takeda Pharmaceutical Co Ltd
Tempest Therapeutics Inc
Teva Pharmaceutical Industries Ltd
The National Institute for Biotechnology in the Negev Ltd
The United Laboratories International Holdings Ltd
Tritech Biopharmaceuticals Co Ltd
TSH Biopharm Corporation Ltd
Uni-Bio Science Group Ltd
Vibe Pharmaceuticals LLC
Vidasym Inc
Viking Therapeutics Inc
Wuxi Hebang Biotechnology Co Ltd
Yooyoung Pharm Co Ltd
Zosano Pharma Corp
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Osteoporosis – Overview

Osteoporosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Osteoporosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteoporosis – Companies Involved in Therapeutics Development

Osteoporosis – Drug Profiles

Osteoporosis – Dormant Projects

Osteoporosis – Discontinued Products

Osteoporosis – Product Development Milestones

Featured News & Press Releases

Aug 10, 2022: Rani Therapeutics announces positive topline results from phase 1 study of RT-102 in osteoporosis

Aug 08, 2022: Rani Therapeutics enters into $45 million loan agreement to support ongoing Ramipril platform advancement and clinical pipeline development

Jul 20, 2022: Alvotech initiates a pharmacokinetic study for AVT03, a proposed biosimilar for Prolia and Xgeva

Jul 20, 2022: Henlius Denosumab Biosimilar HLX14 received clinical trial approval in Australia for the phase 3 MRCT

Jul 18, 2022: Entera Bio announces execution of key regulatory milestones for EB613, the first oral anabolic drug proposed for the treatment of Osteoporosis; Miranda Toledano assumes CEO Position

Jun 17, 2022: Voluntary announcement – First patient has been dosed in an international multicentre phase 3 clinical trial for a biosimilar of denosumab HLX14 (recombinant anti-RANKL human monoclonal antibody injection) for the treatment of postmenopausal osteoporosis in women with high fracture risks in Mainland China

Jun 08, 2022: Radius Health expands Non-US market footprint for TYMLOS

Jun 01, 2022: Radius Health update on Abaloparatide Transdermal System

May 03, 2022: Rani Therapeutics’ RaniPill capsule named winner in the Health category of fast company’s 2022 World Changing Ideas Awards

Apr 29, 2022: Transcenta doses first subject in Phase I osteoporosis drug trial in China

Apr 01, 2022: Thousands of people set to benefit from first new treatment for osteoporosis for over a decade

Mar 23, 2022: Rani Therapeutics announces initiation of phase 1 study of RT-102 oral PTH for osteoporosis

Mar 10, 2022: Amgen keeps dominating Korea’s osteoporosis treatment market

Mar 01, 2022: Radius Health files sNDA for TYMLOS in Men with osteoporosis

Feb 17, 2022: Entera Bio to present at Aegis Virtual Conference on February 23rd

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the targets of the Osteoporosis pipeline drugs market?

    Some of the targets of the Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11, Parathyroid Hormone Receptor, Sclerostin, Estrogen Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase, Peroxisome Proliferator Activated Receptor Gamma, Vitamin D Receptor, and Estrogen Receptor Beta among others.

  • What are the mechanisms of action of the Osteoporosis pipeline drugs market?

    The key mechanism of action of the Osteoporosis pipeline drugs market are Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor, Parathyroid Hormone Receptor Agonist, Sclerostin Inhibitor, Estrogen Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Vitamin D Receptor Agonist, and Estrogen Receptor Antagonist among others.

  • What are the routes of administration in the Osteoporosis pipeline drugs market?

    The routes of administration in the Osteoporosis pipeline drugs market are subcutaneous, oral, parenteral, intravenous, transdermal, inhalational, intramuscular, intravitreal, and topical among others.

  • What are the molecule types in the Osteoporosis pipeline drugs market?

    The molecule types in the Osteoporosis pipeline drugs market are Small Molecule, Monoclonal Antibody, Recombinant Peptide, Recombinant Protein, Synthetic Peptide, Peptide, Biologic, and Cell Therapy among others.

  • Which are the key companies in the Osteoporosis pipeline drugs market?

    Some of the key companies in the Osteoporosis pipeline drugs market are Omeros Corp, Affilogic SAS, Galapagos NV, Luye Pharma Group Ltd, Max Biopharma Inc, Uni-Bio Science Group Ltd, Amgen Inc, Angitia Biopharmaceuticals, Biocon Ltd, Celltrion Inc, and CSPC Pharmaceutical Group Ltd among others.

Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Metabolic Disorders reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more